Abstract
A patient presented with a large thyroid nodule that was eventually diagnosed as a Hürthle cell variant of follicular thyroid carcinoma. The case is unusual in its presentation with locoregional lymph node metastases, generally thought to be characteristic of papillary thyroid carcinoma but not follicular thyroid carcinoma. The patient illustrates the typical presentation of Hürthle cell carcinoma, in that he was of advanced age and the nodule lacked calcification on ultrasonography and was relatively large. The case illustrates the difficulty in differential diagnosis based upon cytology alone and the need for aggressive initial management with surgery and radioiodine when there is pathologic evidence of a highly invasive nature of the tumor. Unfortunately, many of these tumors are either radioiodine uptake negative or radioresistant, and other modalities of therapy are often required.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rossi ED, Martini M, Straccia P, Raffaelli M, Pennacchia I, Marrucci E, Lombardi CP, Pontecorvi A, Fadda G. The cytologic category of oncocytic (Hürthle) cell neoplasm mostly includes low-risk lesions at histology: an institutional experience. Eur J Endocrinol. 2013;169(5):649–55.
Auger M. Hürthle cells in fine-needle aspirates of the thyroid: a review of their diagnostic criteria and significance. Cancer Cytopathol. 2014;122(4):241–9.
Lee KH, Shin JH, Ko ES, Hahn SY, Kim JS, Kim JH, Oh YL. Predictive factors of malignancy in patients with cytologically suspicious for Hürthle cell neoplasm of thyroid nodules. Int J Surg. 2013;11(9):898–902.
Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH. Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid. World J Surg. 2008;32(5):702–7.
Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N. Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol. 2010;101(7):582–6.
Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, Clark OH, Kebebew E. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hürthle-cell neoplasms of the thyroid. Am J Surg. 2010;200:41–6.
Yip L, Wharry LI, Armstrong MJ, Silbermann A, McCoy KL, Stang MT, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg. 2014;260:163–7.
McCoy KL, Carty SE, Armstrong MJ, Seethala RR, Ohori NP, Kabaker AS, et al. Intraoperative pathologic examination in the era of molecular testing for differentiated thyroid cancer. J Am Coll Surg. 2012;215:546–54.
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569–80.
Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular pattern cancers. J Clin Endocrinol Metab. 2013;98:E914–22.
Maizlin ZV, Wiseman SM, Vora P, Kirby JM, Mason AC, Filipenko D, Brown JA. Hürthle cell neoplasms of the thyroid: sonographic appearance and histologic characteristics. J Ultrasound Med. 2008;27(5):751–7.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov Y, et al. American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015; 24.
Riemann B, Uhrhan K, Dietlein M, Schmidt D, Kuwert T, et al. Diagnostic value and therapeutic impact of (18)F-FDG-PEET-CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin. 2013;53:1–6.
Pauleau G, Palazzo FF, Essamet W, Sebag F, Taieb D. Hürthle cell neoplasms: a new differential diagnosis of 18F-FDOPA-avid thyroid nodules? J Clin Endocrinol Metab. 2013;98:865–6.
Lee J, Hasteh F. Oncocytic variant of papillary thyroid carcinoma associated with Hashimoto’s thyroiditis: a case report and review of the literature. Diagn Cytopathol. 2009;37(8):600–6.
Mai KT, Khanna P, Yazdi HM, Perkins DG, Veinot JP, Thomas J, Lamba M, Nair BD. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular. Hürthle cell and papillary thyroid carcinoma. Pathology. 2002;34:239–44.
Mills SC, Haq M, Smellie WJ, Harmer C. Hürthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2009;35(3):230–4.
Bishop JA, Wu G, Tufano RP, Westra WH. Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland. Thyroid. 2012;22(7):690–4.
Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hürthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013;154:1246–53.
Haigh PI, Urbach DR. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery. 2005;138:1152–7.
Ganly I, Ricarte FJ, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA. Genomic dissection of Hürthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013;98:E962–72.
Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B. Prognostic factors of recurrence in encapsulated Hürthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006;106:1669–76.
Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, et al. Does Hürthle cell carcinoma of the thyroid have a poorer prognosis than ordinary follicular thyroid carcinoma? Ann Surg Oncol. 2013;20(9):2944–50.
Takashima S, Sone S, Takayama F, Wang Q, Kobayashi T, Horii A, Yoshida JI. Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis. AJNR Am J Neuroradiol. 1998;19:509–13.
Gross ND, Weissman JL, Talbot JM, Andersen PE, Wax MK, Cohen JI. MRI detection of cervical metastasis from differentiated thyroid carcinoma. Laryngoscope. 2001;111:1905–9.
Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hürthle cell carcinoma? Int J Radiat Oncol Biol Phys. 2003;56:1067–72.
Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. Am J Roentgenol. 2002;178:699–704.
Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery. 2001;130:971–7.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wartofsky, L. (2016). A Patient with a Large Hürthle Cell Carcinoma of the Thyroid and Nodal Metastases. In: Cooper, D., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22401-5_24
Download citation
DOI: https://doi.org/10.1007/978-3-319-22401-5_24
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22400-8
Online ISBN: 978-3-319-22401-5
eBook Packages: MedicineMedicine (R0)